Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

Satish Sanku Chander Rao, S. A.C. Dundas, C. D. Holdsworth, P. A. Cann, K. R. Palmer, C. L. Corbett

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Olsalazine (2 g/day) sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p < 0.001). The proportion of unformed stools was also decreased, but to a lesser extent (p < 0.05) in those taking olsalazine (78% v 55%; p < 0.001) compared with those taking sulphasalazine (72% v 28%; p < 0.001). There was a diminution in the proportion of stools containing blood in both groups (olsalazine: 61% v 22%; p < 0.001/sulphasalazine: 67% v 37%; p < 0.001). Sigmoidoscopic and histological appearances and clinical activity improved significantly and to a similar extent in both groups. Intolerance was encountered in two patients on olsalazine and four on sulphasalazine; intolerance to sulphasalazine being even higher (five of seven patients) in a preliminary study using a dose of sulphasalazine releasing the same amount of 5-aminosalicylic acid as 2 g olsalazine. Olsalazine was at least as effective as sulphasalazine in the treatment of new patients with distal colitis, and in a dose releasing an equivalent amount of 5-aminosalicylic acid was better tolerated.

Original languageEnglish (US)
Pages (from-to)675-679
Number of pages5
JournalGut
Volume30
Issue number5
DOIs
StatePublished - Jan 1 1989

Fingerprint

Sulfasalazine
Ulcerative Colitis
Double-Blind Method
Mesalamine
Colitis
olsalazine
Biopsy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rao, S. S. C., Dundas, S. A. C., Holdsworth, C. D., Cann, P. A., Palmer, K. R., & Corbett, C. L. (1989). Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut, 30(5), 675-679. https://doi.org/10.1136/gut.30.5.675

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. / Rao, Satish Sanku Chander; Dundas, S. A.C.; Holdsworth, C. D.; Cann, P. A.; Palmer, K. R.; Corbett, C. L.

In: Gut, Vol. 30, No. 5, 01.01.1989, p. 675-679.

Research output: Contribution to journalArticle

Rao, SSC, Dundas, SAC, Holdsworth, CD, Cann, PA, Palmer, KR & Corbett, CL 1989, 'Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study', Gut, vol. 30, no. 5, pp. 675-679. https://doi.org/10.1136/gut.30.5.675
Rao SSC, Dundas SAC, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut. 1989 Jan 1;30(5):675-679. https://doi.org/10.1136/gut.30.5.675
Rao, Satish Sanku Chander ; Dundas, S. A.C. ; Holdsworth, C. D. ; Cann, P. A. ; Palmer, K. R. ; Corbett, C. L. / Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. In: Gut. 1989 ; Vol. 30, No. 5. pp. 675-679.
@article{61718eb412a34f748042a75766055f7e,
title = "Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study",
abstract = "Olsalazine (2 g/day) sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p < 0.001). The proportion of unformed stools was also decreased, but to a lesser extent (p < 0.05) in those taking olsalazine (78{\%} v 55{\%}; p < 0.001) compared with those taking sulphasalazine (72{\%} v 28{\%}; p < 0.001). There was a diminution in the proportion of stools containing blood in both groups (olsalazine: 61{\%} v 22{\%}; p < 0.001/sulphasalazine: 67{\%} v 37{\%}; p < 0.001). Sigmoidoscopic and histological appearances and clinical activity improved significantly and to a similar extent in both groups. Intolerance was encountered in two patients on olsalazine and four on sulphasalazine; intolerance to sulphasalazine being even higher (five of seven patients) in a preliminary study using a dose of sulphasalazine releasing the same amount of 5-aminosalicylic acid as 2 g olsalazine. Olsalazine was at least as effective as sulphasalazine in the treatment of new patients with distal colitis, and in a dose releasing an equivalent amount of 5-aminosalicylic acid was better tolerated.",
author = "Rao, {Satish Sanku Chander} and Dundas, {S. A.C.} and Holdsworth, {C. D.} and Cann, {P. A.} and Palmer, {K. R.} and Corbett, {C. L.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1136/gut.30.5.675",
language = "English (US)",
volume = "30",
pages = "675--679",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

AU - Rao, Satish Sanku Chander

AU - Dundas, S. A.C.

AU - Holdsworth, C. D.

AU - Cann, P. A.

AU - Palmer, K. R.

AU - Corbett, C. L.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Olsalazine (2 g/day) sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p < 0.001). The proportion of unformed stools was also decreased, but to a lesser extent (p < 0.05) in those taking olsalazine (78% v 55%; p < 0.001) compared with those taking sulphasalazine (72% v 28%; p < 0.001). There was a diminution in the proportion of stools containing blood in both groups (olsalazine: 61% v 22%; p < 0.001/sulphasalazine: 67% v 37%; p < 0.001). Sigmoidoscopic and histological appearances and clinical activity improved significantly and to a similar extent in both groups. Intolerance was encountered in two patients on olsalazine and four on sulphasalazine; intolerance to sulphasalazine being even higher (five of seven patients) in a preliminary study using a dose of sulphasalazine releasing the same amount of 5-aminosalicylic acid as 2 g olsalazine. Olsalazine was at least as effective as sulphasalazine in the treatment of new patients with distal colitis, and in a dose releasing an equivalent amount of 5-aminosalicylic acid was better tolerated.

AB - Olsalazine (2 g/day) sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p < 0.001). The proportion of unformed stools was also decreased, but to a lesser extent (p < 0.05) in those taking olsalazine (78% v 55%; p < 0.001) compared with those taking sulphasalazine (72% v 28%; p < 0.001). There was a diminution in the proportion of stools containing blood in both groups (olsalazine: 61% v 22%; p < 0.001/sulphasalazine: 67% v 37%; p < 0.001). Sigmoidoscopic and histological appearances and clinical activity improved significantly and to a similar extent in both groups. Intolerance was encountered in two patients on olsalazine and four on sulphasalazine; intolerance to sulphasalazine being even higher (five of seven patients) in a preliminary study using a dose of sulphasalazine releasing the same amount of 5-aminosalicylic acid as 2 g olsalazine. Olsalazine was at least as effective as sulphasalazine in the treatment of new patients with distal colitis, and in a dose releasing an equivalent amount of 5-aminosalicylic acid was better tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0024359916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024359916&partnerID=8YFLogxK

U2 - 10.1136/gut.30.5.675

DO - 10.1136/gut.30.5.675

M3 - Article

VL - 30

SP - 675

EP - 679

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -